Cell and Gene Therapy, Industry
September 21, 2023
Via: Biopharm InternationalOn Sept. 20, 2023, Alexion, AstraZeneca’s rare disease group, completed the purchase and license agreement for a portfolio of preclinical rare disease gene therapy programs and enabling technologies from Pfizer. The acquisition cost AstraZeneca up to $1 billion, with the […]
Cell and Gene Therapy, Industry
September 21, 2023
Via: Biopharma DiveLike many biotechnology companies, Seraxis has an ambitious aim. The company wants to transform the lives of millions of diabetics who must take insulin every day to control their blood sugar levels. Its approach: use a stem cell line generated […]
September 20, 2023
Via: Drugs.comIn a surprising move, the U.S. Food and Drug Administration (FDA) has opted not to approve a needle-free alternative to the EpiPen for emergency treatment of severe allergic reactions. Approval of the Neffy nasal spray was widely anticipated. An FDA […]
September 18, 2023
Via: Pharma TimesThe updated vaccines more closely target current circulating variants The US Food and Drug Administration (FDA) has granted approval for Pfizer/BioNTech and Moderna’s updated COVID-19 vaccines, to tackle currently circulating variants. As previously recommended by the FDA, both vaccines have […]
September 18, 2023
Via: PMLiVEMillions of eligible people in England can now book their vaccine via the NHS website, the NHS app, or by calling 119 for free if they do not have access online. From this week, people aged 65 and over, pregnant […]
September 14, 2023
Via: PMLiVEThe recommendation comes after the US Food and Drug Administration (FDA) approved updated COVID-19 vaccines from Pfizer/BioNTech and Moderna, which will be available later this week. Novavax’s protein-based updated COVID-19 vaccine is currently still under FDA review and showed promise […]
September 13, 2023
Via: Biopharm InternationalDrug development is inherently costly and time-intensive, with potential attrition a persistent burden on companies’ finances (1). As companies gain a deeper understanding of cell and molecular biology and seek to develop more complex therapeutics for patient populations, they will […]
September 13, 2023
Via: Biopharma DiveAdvisers to the Food and Drug Administration on Wednesday endorsed Alnylam Pharmaceuticals’ drug Onpattro for a rare heart condition, despite questions from agency scientists over the degree of benefit offered by the RNA-based therapy. The advisory committee’s 9-3 vote sets […]
Cell and Gene Therapy, Industry
September 11, 2023
Via: Biopharma DiveNovartis has stopped work on a gene therapy candidate it acquired a little under two years ago, according to an investor in the company the Swiss drugmaker bought. The decision to discontinue research follows a recommendation from a data monitoring […]
September 11, 2023
Via: Drugs.comIn a finding that should ease the minds of Americans ahead of another flu season, this year’s vaccines have already cut the risk of hospitalization in half during the South American winter, health officials report. Even better, the flu virus […]
September 7, 2023
Via: Drugs.comNew COVID-19 booster shots could soon pass the needed hurdles for vaccinations to begin next week. Sources familiar with U.S. Food and Drug Administration plans say boosters could be approved as soon as Friday, NBC News reported. The U.S. Centers […]
September 7, 2023
Via: Biopharma DiveSeagen is the biotech sector’s leading developer of antibody-drug conjugates, which deliver cell-killing toxins to diseased cells by attaching them to an antibody that seeks out proteins on tumor cells. Its first, Adcetris, is on track to become a blockbuster […]
Cell and Gene Therapy, Industry
September 5, 2023
Via: Biopharma DiveSuccess in the clinic would boost the RNA editing field as well as Wave. Broadly speaking, the technology is designed to edit specific sites in an RNA transcript without making permanent changes to a person’s genome. It’s an approach that’s […]
Cell and Gene Therapy, Industry
September 5, 2023
Via: Pharma TimesThe funding will boost the University of Nottingham spinout’s development of bone regeneration treatment TherageniX, a company developing a dry powder gene therapy for bone graft augmentation, and the institution from which it emerged, the University of Nottingham, have been […]
September 5, 2023
Via: PMLiVEFEATUREDThe investment follows the launch of the company’s new respiratory syncytial virus (RSV) vaccine, Arexvy. Designed to increase the efficiency of manufacturing processes and reduce environmental impact, the new unit will handle freeze-dried vaccines, including Arexvy, as well as the […]
Cell and Gene Therapy, Industry
August 31, 2023
Via: PMLiVEJeff Ajer, BioMarin’s executive vice president and chief commercial officer, said the announcement “represents an important milestone” for the haemophilia community, as well as for patients and physicians around the world seeking access to the therapy. Haemophilia treatment centres in […]
August 31, 2023
Via: PMLiVEThe transaction gives the Danish drugmaker full rights to develop and commercialise Embark Biotech’s lead asset targeting obesity and other cardiometabolic diseases. In exchange, Embark Biotech will receive an upfront cash payment of €15m and will also be eligible to […]
August 30, 2023
Via: Kaiser Health NewsThe Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major turning point in a long-fought battle to control ever-rising drug prices for […]
Cell and Gene Therapy, Industry
August 30, 2023
Via: PMLiVEThe trial results were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark. Parkinson’s disease is the fastest-growing neurodegenerative disease in the world and causes parts of the brain to become progressively damaged over many […]
August 29, 2023
Via: Biopharma DiveThe Food and Drug Administration on Monday approved wider use of a drug important to Bristol Myers Squibb’s future, clearing the medicine for people newly diagnosed with a cancer-like disease of the bone marrow. Called Reblozyl, the drug has been […]